"The Sweetest Dose: Your Complete
300-Step Journey to Mastering
Pharmacology 230"Questions And
Answers With Rationales
SECTION 1: PHARMACOKINETICS (The Body's Journey with
the Drug)
1. What is the definition of Pharmacokinetics?
A: What the body does to the drug.
R: It encompasses the processes of Absorption, Distribution,
Metabolism, and Excretion (ADME).
2. Which route of administration provides the fastest onset of
action?
A: Intravenous (IV).
R: IV administration bypasses the absorption phase entirely,
delivering the drug directly into the systemic circulation.
3. What is the "first-pass effect"?
A: The metabolism of a drug by the liver before it reaches the
systemic circulation.
R: Orally administered drugs are absorbed from the GI tract
and travel via the portal vein to the liver, where a significant
portion can be metabolized, reducing its bioavailability.
,4. A drug has a half-life (t½) of 4 hours. How long will it take
to reach a steady state?
A: Approximately 20 hours (4 hours x 5).
R: It takes about 4-5 half-lives for a drug to reach steady-
state plasma concentration when given at a constant rate.
5. What is the therapeutic index (TI)?
A: A ratio that compares the toxic dose of a drug to its
effective dose (TD50/ED50).
R: A high TI indicates a wide margin of safety (e.g., penicillin).
A low TI indicates a narrow margin (e.g., digoxin, warfarin)
and requires close monitoring.
6. What does the term "bioavailability" mean?
A: The fraction of an administered drug that reaches the
systemic circulation in an unchanged form.
R: IV drugs have 100% bioavailability. Oral drugs have less
due to incomplete absorption and first-pass metabolism.
7. How does a highly protein-bound drug affect the action of
another drug?
A: It can displace the other drug, increasing its free (active)
concentration and potentially leading to toxicity.
R: Only the free (unbound) drug is pharmacologically active.
Displacement from protein binding sites can cause a sudden
increase in the active drug.
8. What is the primary organ responsible for drug
metabolism?
, A: The Liver.
R: The liver contains the Cytochrome P450 (CYP450) enzyme
system, which is primarily responsible for Phase I and Phase II
metabolic reactions.
9. What is the primary organ responsible for drug excretion?
A: The Kidneys.
R: The kidneys filter the blood, and drugs are excreted in the
urine via glomerular filtration, tubular secretion, and tubular
reabsorption.
10. What is an "agonist" drug?
A: A drug that binds to a receptor and activates it, producing
a response.
R: It mimics the action of the endogenous ligand (e.g.,
morphine is an agonist at opioid receptors).
11. What is an "antagonist" drug?
A: A drug that binds to a receptor but does not activate it,
blocking the action of an agonist.
R: It has no intrinsic activity but prevents the agonist from
binding (e.g., naloxone is an antagonist at opioid receptors).
12. What is a "partial agonist"?
A: A drug that binds to a receptor and produces a sub-
maximal response, even at full receptor occupancy.
R: It has lower efficacy than a full agonist (e.g.,
buprenorphine is a partial agonist at opioid receptors).
, 13. What is an "idiosyncratic reaction"?
A: An unexpected, genetically determined reaction to a drug.
R: It is not related to the drug's known pharmacological
action (e.g., hemolytic anemia in patients with G6PD
deficiency after taking sulfonamides).
14. What is the difference between a "side effect" and a
"toxic effect"?
A: A side effect is a predictable, dose-related, and often
unavoidable secondary effect. A toxic effect is an adverse
effect that results from an excessive dose (overdosage) or a
buildup of the drug.
R: Side effects are mild and manageable (e.g., drowsiness
with antihistamines), while toxic effects are severe and
harmful (e.g., liver failure with acetaminophen overdose).
15. A patient is given a drug that is a weak acid. In which
environment will it be better absorbed?
A: In an acidic environment (like the stomach).
R: Weak acids are uncharged (more lipid-soluble) in acidic
environments, which allows them to passively diffuse across
cell membranes.
SECTION 2: AUTONOMIC NERVOUS SYSTEM &
NEUROPHARMACOLOGY
300-Step Journey to Mastering
Pharmacology 230"Questions And
Answers With Rationales
SECTION 1: PHARMACOKINETICS (The Body's Journey with
the Drug)
1. What is the definition of Pharmacokinetics?
A: What the body does to the drug.
R: It encompasses the processes of Absorption, Distribution,
Metabolism, and Excretion (ADME).
2. Which route of administration provides the fastest onset of
action?
A: Intravenous (IV).
R: IV administration bypasses the absorption phase entirely,
delivering the drug directly into the systemic circulation.
3. What is the "first-pass effect"?
A: The metabolism of a drug by the liver before it reaches the
systemic circulation.
R: Orally administered drugs are absorbed from the GI tract
and travel via the portal vein to the liver, where a significant
portion can be metabolized, reducing its bioavailability.
,4. A drug has a half-life (t½) of 4 hours. How long will it take
to reach a steady state?
A: Approximately 20 hours (4 hours x 5).
R: It takes about 4-5 half-lives for a drug to reach steady-
state plasma concentration when given at a constant rate.
5. What is the therapeutic index (TI)?
A: A ratio that compares the toxic dose of a drug to its
effective dose (TD50/ED50).
R: A high TI indicates a wide margin of safety (e.g., penicillin).
A low TI indicates a narrow margin (e.g., digoxin, warfarin)
and requires close monitoring.
6. What does the term "bioavailability" mean?
A: The fraction of an administered drug that reaches the
systemic circulation in an unchanged form.
R: IV drugs have 100% bioavailability. Oral drugs have less
due to incomplete absorption and first-pass metabolism.
7. How does a highly protein-bound drug affect the action of
another drug?
A: It can displace the other drug, increasing its free (active)
concentration and potentially leading to toxicity.
R: Only the free (unbound) drug is pharmacologically active.
Displacement from protein binding sites can cause a sudden
increase in the active drug.
8. What is the primary organ responsible for drug
metabolism?
, A: The Liver.
R: The liver contains the Cytochrome P450 (CYP450) enzyme
system, which is primarily responsible for Phase I and Phase II
metabolic reactions.
9. What is the primary organ responsible for drug excretion?
A: The Kidneys.
R: The kidneys filter the blood, and drugs are excreted in the
urine via glomerular filtration, tubular secretion, and tubular
reabsorption.
10. What is an "agonist" drug?
A: A drug that binds to a receptor and activates it, producing
a response.
R: It mimics the action of the endogenous ligand (e.g.,
morphine is an agonist at opioid receptors).
11. What is an "antagonist" drug?
A: A drug that binds to a receptor but does not activate it,
blocking the action of an agonist.
R: It has no intrinsic activity but prevents the agonist from
binding (e.g., naloxone is an antagonist at opioid receptors).
12. What is a "partial agonist"?
A: A drug that binds to a receptor and produces a sub-
maximal response, even at full receptor occupancy.
R: It has lower efficacy than a full agonist (e.g.,
buprenorphine is a partial agonist at opioid receptors).
, 13. What is an "idiosyncratic reaction"?
A: An unexpected, genetically determined reaction to a drug.
R: It is not related to the drug's known pharmacological
action (e.g., hemolytic anemia in patients with G6PD
deficiency after taking sulfonamides).
14. What is the difference between a "side effect" and a
"toxic effect"?
A: A side effect is a predictable, dose-related, and often
unavoidable secondary effect. A toxic effect is an adverse
effect that results from an excessive dose (overdosage) or a
buildup of the drug.
R: Side effects are mild and manageable (e.g., drowsiness
with antihistamines), while toxic effects are severe and
harmful (e.g., liver failure with acetaminophen overdose).
15. A patient is given a drug that is a weak acid. In which
environment will it be better absorbed?
A: In an acidic environment (like the stomach).
R: Weak acids are uncharged (more lipid-soluble) in acidic
environments, which allows them to passively diffuse across
cell membranes.
SECTION 2: AUTONOMIC NERVOUS SYSTEM &
NEUROPHARMACOLOGY
